Preliminary data from an ongoing phase 1 dose-escalation study of CCX559, an orally administered small molecule PD-L1 inhibitor, in patients with advanced solid tumors

被引：0
|
作者：
Tapia, Gonzalo
Lundy, Joanne
Richardson, Gary Edward
Zhao, Niky
Ebsworth, Karen
Yue, Huibin
Miao, Shichang
Degoma, Emil
Jain, Rita
Schall, Thomas J.
Sullivan, Kathleen
Zhang, Penglie
De Souza, Paul L.
机构：
[1] Univ Adelaide, ICON Canc Ctr, Adelaide, SA, Australia
[2] Paso Med, Frankston, Vic, Australia
[3] Cabrini Res, Malvern, Vic, Australia
[4] ChemoCentryx, San Carlos, CA USA
[5] ChemoCentryx Inc, San Carlos, CA USA
[6] Univ Western Sydney, Sch Med, Campbelltown, NSW, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2593
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase 1 dose-escalation study of single-agent veliparib in Japanese patients with advanced solid tumors
    Nishikawa, Tadaaki
    Matsumoto, Koji
    Tamura, Kenji
    Yoshida, Hiroyuki
    Imai, Yuichi
    Miyasaka, Aki
    Onoe, Takuma
    Yamaguchi, Satoshi
    Shimizu, Chikako
    Yonemori, Kan
    Shimoi, Tatsunori
    Yunokawa, Mayu
    Xiong, Hao
    Nuthalapati, Silpa
    Hashiba, Hideyuki
    Kiriyama, Tsukasa
    Leahy, Terri
    Komarnitsky, Philip
    Fujiwara, Keiichi
    CANCER SCIENCE, 2017, 108 (09) : 1834 - 1842
  • [22] A phase Ib dose escalation study of the OX40 agonist MOXR0916 and the PD-L1 inhibitor atezolizumab in patients with advanced solid tumors.
    Infante, Jeffrey R.
    Hansen, Aaron Richard
    Pishvaian, Michael J.
    Chow, Laura Quan Man
    McArthur, Grant A.
    Bauer, Todd Michael
    Liu, Stephen V.
    Sandhu, Shahneen Kaur
    Tsai, Frank Yung -Chin
    Kim, Jeong
    Stefanich, Eric
    Li, Chi -Chung
    Gilber, Houston
    Mccall, Bruce
    Anderson, Maria S.
    Huseni, Mahrukh
    Rhee, Ina Park
    Siu, Lillian L.
    Gordon, Michael S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [23] Preliminary efficacy from an ongoing phase 1 dose escalation study of seclidemstat (SP-2577) in patients (pts) with advanced solid tumors (AST).
    Chawla, Sant P.
    Chua-Alcala, Victoria S.
    Sachdev, Jasgit C.
    Wages, David S.
    Stenehjem, David D.
    Santiesteban, Daniela Y.
    Mirza, Nadeem Q.
    Gordon, Michael S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [24] A PHASE 1A/1B DOSE-ESCALATION STUDY OF INTRAVENOUSLY ADMINISTERED SB 11285 ALONE AND IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS
    Abbas, A.
    Strauss, J.
    Janku, F.
    Karim, R.
    Olszanski, A.
    Luke, J. J.
    Leach, K.
    Iyer, R.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A7 - A8
  • [25] A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered every three weeks in patients with advanced solid tumors
    Mross, K. B.
    Scheulen, M. E.
    Frost, A.
    Scharr, D.
    Richly, H.
    Nokay, B.
    Lee, K.
    Hilbert, J.
    Fleischer, F.
    Fietz, O.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [26] Phase I dose-escalation study of E7080, a multikinase inhibitor, in patients with advanced solid tumors
    Nemunaitis, J. J.
    Senzer, N. N.
    Kurzrock, R.
    Ng, C. S.
    Das, A.
    Atienza, R. S.
    Zang, E. A.
    Jansen, M.
    Ashworth, S.
    Hong, D. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [27] A phase I dose-escalation study of RAD001 administered daily to Japanese patients with advanced solid tumors
    Doi, T.
    Ohtsu, A.
    Nakagawa, K.
    Okamoto, I.
    Kurei, K.
    Kobayashi, K.
    EJC SUPPLEMENTS, 2007, 5 (04): : 114 - 114
  • [28] A phase 1/1b, open-label, dose-escalation study of PD-1 inhibitor, cetrelimab alone and in combination with FGFR inhibitor, erdafitinib in Japanese patients with advanced solid tumors
    Yamamoto, Noboru
    Kuboki, Yasutoshi
    Harano, Kenichi
    Koyama, Takafumi
    Kondo, Shunsuke
    Hagiwara, Akiko
    Suzuki, Noriko
    Fujikawa, Ei
    Toyoizumi, Kiichiro
    Mukai, Mayumi
    Doi, Toshihiko
    INVESTIGATIONAL NEW DRUGS, 2024, 42 (04) : 376 - 385
  • [29] Phase 1 dose-escalation study of E7820, a novel anti-angiogenic agent, administered orally twice-daily to patients with advanced, refractory solid tumors
    Kristeleit, R.
    Plummer, R.
    Ranson, M.
    Slater, S.
    Witteveen, P. O.
    Reyderman, L.
    De las Heras, B.
    Verbel, D.
    Ink, B.
    Schellens, J. H. M.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S165 - S165
  • [30] Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial
    Patnaik, Amita
    Weiss, Glen J.
    Rasco, Drew W.
    Blaydorn, Lisa
    Mirabella, Amy
    Beeram, Murali
    Guo, Wei
    Lu, Sharon
    Danaee, Hadi
    McEachern, Kristen
    Im, Ellie
    Sachdev, Jasgit C.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (01) : 93 - 103
12345